Tolerability of Concurrent Chemoradiotherapy with Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Physician- and Patient-reported Outcomes

Thompson C.; Sanderson B.; Liptrot T.; Wylie J.; Choudhury A.; Logue J.

首页> 外文期刊>Clinical oncology >Tolerability of Concurrent Chemoradiotherapy with Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Physician- and Patient-reported Outcomes

【24h】

Tolerability of Concurrent Chemoradiotherapy with Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Physician- and Patient-reported Outcomes

机译：吉西他滨（GemX）联合放化疗的联合耐受性，在有和没有事先新辅助化疗的情况下对肌肉浸润性膀胱癌的耐受性：医师和患者报告的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical oncology》 |2015年第3期|共1页
作者
Thompson C.; Sanderson B.; Liptrot T.; Wylie J.; Choudhury A.; Logue J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Tolerability of Concurrent Chemoradiotherapy with Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Physician- and Patient-reported Outcomes [J] . Thompson C., Sanderson B., Liptrot T., Clinical oncology . 2015,第3期

机译：吉西他滨（GemX）联合放化疗的联合耐受性，在有和没有事先新辅助化疗的情况下对肌肉浸润性膀胱癌的耐受性：医师和患者报告的结果
2. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer [J] . YuhB.E., RuelN., WilsonT.G., The Journal of Urology . 2013,第5期

机译：新辅助顺铂联合吉西他滨化疗治疗肌肉浸润性膀胱癌的临床结果汇总分析
3. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer [J] . Fahmy Omar, Khairul-Asri Mohd Ghani, Schubert Tina, Urologic oncology . 2018,第2期

机译：对肌肉侵袭性膀胱癌或没有Neoadjuvant化疗后染色体治疗和自由基膀胱切除术后肿瘤长期结果的系统评价和荟萃分析
4. Predictive Biomarkers for Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer: A survey [C] . Hisham Abdeltawab, Fahmi Khalifa, Mohammed Ghazal, IEEE International Symposium on Signal Processing and Information Technology . 2018

机译：肌肉浸润性膀胱癌新辅助化疗反应的预测性生物标志物：一项调查
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute [O] . Ka Chai Eric Lee, Wing Ho Mui, Wai Chan, 2019

机译：使用吉西他滨和顺铂在肌肉侵袭性膀胱癌中的Neoadjuvant化疗的结果：对单一研究所的患者和治疗因素的回顾性分析
7. Tolerability of Concurrent Chemoradiotherapy with Gemcitabine (GemX), with and without prior Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer [O] . Thompson, Catherine, Joseph, Nuradh, Sanderson, Benjamin, 2017

机译：同时放化疗与吉西他滨（GemX），有和没有先前新辅助化疗治疗肌肉浸润性膀胱癌的耐受性

Tolerability of Concurrent Chemoradiotherapy with Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Physician- and Patient-reported Outcomes

著录项

相似文献

相关主题

期刊订阅